Print
16 March 2016
BioPharm International
The BioPhorum Operations Group is inviting industry stakeholders including academics, supply partner R&D heads, regulators, and regional hubs to participate in the group’s Technology Roadmap for the future of biopharmaceuticals. The Technology Roadmap is being developed in response to the complexity of the current industry structure, which the group says has held back innovation with many end users trying to develop new technologies in isolation, and resulting in suppliers having to guess end user requirements. The group currently has more than 100 active participants in the roadmapping process, consisting of a steering committee and six teams working to address key technology challenges.
Eighteen BioPhorum member companies are currently developing the roadmap, and the group is hoping to add additional participants to the project. When complete, the Technology Roadmap will be available for free and updated and published on a regular basis.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.